The integration of resistin as a prognostic biomarker, together with several classic predictive markers such as the lesion volume, NIHSS score, or presence of comorbidities, could enhance the current protocols for managing AIS patients, allowing for a more precise risk stratification and personalized care. Here, RETN is linked to androgen insensitivity syndrome.